Tirzepatide is the first agent that functions as a dual agonist for the two main human GLP-1 and GIP incretins, a promising drug against both T2D and obesity [34,35,36,37]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.